Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors – a single center experience

OBJECTIVE: To evaluate hematological, cytogenetic and molecular responses as well as the overall, progression-free and event-free survivals of chronic myeloid leukemia patients treated with a third tyrosine kinase inhibitor after failing to respond to imatinib and nilotinib/dasatinib. METHODS: Bone...

Descripción completa

Detalles Bibliográficos
Autores principales: Ribeiro, Beatriz Felicio, Miranda, Eliana C M, de Albuquerque, Dulcinéia Martins, Delamain, Márcia T, Oliveira-Duarte, Gislaine, Almeida, Maria Helena, Vergílio, Bruna, da Silveira, Rosana Antunes, Oliveira-Duarte, Vagner, Lorand-Metze, Irene, De Souza, Carmino A, Pagnano, Katia B B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo 2015
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4518767/
https://www.ncbi.nlm.nih.gov/pubmed/26247667
http://dx.doi.org/10.6061/clinics/2015(08)04

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4518767/
https://www.ncbi.nlm.nih.gov/pubmed/26247667
http://dx.doi.org/10.6061/clinics/2015(08)04

Ejemplares similares